 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
AMAG Pharmaceuticals, Inc. (AMAG) develops and commercializes specialty pharmaceutical products.
The company markets Feraheme (ferumoxytol) injection for use as an intravenous (IV) iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. It markets Feraheme in the United States and Canada; and as Rienso in the European Union.
The company sells Feraheme to authorized wholesalers and specialty distributors. AMAG Pharmaceuticals, Inc. has a license, development, and commercialization agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Feraheme/Rienso as a therapeutic agent in Europe, certain Asia-Pacific countries, the Commonwealth of Independent States, Canada, India, and Turkey; and collaboration and exclusive license agreement with 3SBio for the development and commercialization of Feraheme as an IV iron replacement therapeutic agent in China.
Shares are heading higher in a "bullish Cup & Handle"; higher share prices are expected for this stock.
52-Week Trading Range: $16.49 to $48.50
Entry Point: $46.68
Stop Loss: $44.35
Target Price: $51.35
AMAG fell below our stop loss. Closed at $44.20.
